RaySearch Laboratories AB (publ) has received FDA 510(k) clearance for
its RayStation® treatment planning system.
RayStation® is RaySearch’s proprietary complete treatment planning
system that integrates all RaySearch’s advanced treatment planning
solutions into one flexible system. It includes functionality such as
RaySearch’s market-leading algorithms for IMRT and VMAT optimization,
highly accurate dose engines for both photon and proton therapy and will
have full support for 4D adaptive radiation therapy. The system is built
on the latest software architecture and has a graphical user interface
offering state-of-the-art usability.
RaySearch’s business model is based on selling software modules through
partnerships with leading medical technology companies. RaySearch’s
modules are integrated into the partners’ systems and the partners have
all contacts with the clinics. As a complement to this partner-based
business model, RayStation® offers the possibility to collaborate
directly with a few selected leading research-intensive clinics. This
type of collaboration gives RaySearch the freedom to develop innovative
solutions directly in a clinical environment, which is a prerequisite
for securing the company’s long-term position as a leading supplier of
advanced radiation therapy software.
In June 2009 a first agreement was signed in Europe with the German
clinic WPE where RayStation® is planned to be clinically operational in
2010. Receiving 510(k) clearance means that RaySearch can now market
RayStation® in the US and enter similar collaboration agreements in that
region too.
”The fact that we now have our own treatment planning system with FDA
clearance is a milestone of strategic importance,” says Johan Löf, CEO
of RaySearch. ”We have no intentions to go out broadly to a large number
of clinics so this does not mean that we alter our business model in a
significant way. However, RayStation® gives us the possibility to
develop the solutions of the future together with some of the world’s
leading clinics, which is extremely important for us over the long
term,” concludes Johan Löf.
Research project receives 25 million U.S. dollars to develop drugs against childhood cancers